You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

  • Authors: Nadia Harbeck, MD; William J. Gradishar, MD; Sarah Donahue, MPH, NP, AOCNP
  • CME / ABIM MOC / CE Released: 11/17/2023
  • Valid for credit through: 11/17/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, obstetrician/gynecologists, surgeons, pharmacists, and nurses.

The goal of this activity is for learners to be better able to appreciate the nuances of selecting therapy and maintaining persistence to therapy through an in-depth discussion that will expand upon expert insights and best practices.

Upon completion of this activity, participants will be able to:

  • Explain the clinical data associated with therapies for patients with high-risk, hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC)
  • Select the most optimal adjuvant therapy for a patient with high-risk, HR-positive/HER2-negative EBC
  • Employ strategies to improve persistence to adjuvant therapy in patients with high-risk, HR-positive/HER2-negative EBC
  • Utilize an interprofessional approach to select and manage adjuvant treatment in patients with high-risk, HR-positive/HER2-negative EBC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Nadia Harbeck, MD

    Director, Breast Center
    Full Professor
    Department of Obstetrics and Gynecology
    LMU University Hospital
    Munich, Germany

    Disclosures

    Nadia Harbeck, MD, has the following relevant financial relationships:
    Consultant or advisor for: Gilead Sciences, Inc.; Novartis; Roche; Sandoz; Sanofi; Seagen, Inc.
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme, Corp.; Novartis; Pierre Fabre; Pfizer, Inc.; Roche; Sandoz; Sanofi; Seagen, Inc.; Viatris
    Research funding from: AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Merck Sharp & Dohme, Corp.; Pfizer, Inc.; Roche

Faculty

  • William J. Gradishar, MD

    Professor of Oncology
    Betsy Bramsen Professor of Breast Oncology
    Chief of Hematology and Oncology
    Robert H. Lurie Comprehensive Cancer Center
    Feinberg School of Medicine
    Northwestern University
    Chicago, Illinois, United States

    Disclosures

    William J. Gradishar, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Merck; Stemline
    Other: IDMC: Gilead Sciences, Inc.; Lilly; Novartis

  • Sarah Donahue, MPH, NP, AOCNP

    Carol Franc Buck Breast Cancer Center
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California, United States

    Disclosures

    Sarah Donahue, MPH, NP, AOCNP, has no relevant financial relationships.

Editor

  • Victoria Phoenix, BS

    Medical Education Director, Medscape, LLC

    Disclosures

    Victoria Phoenix, BS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Maria Morales, MSN, RN, CLNC

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Maria Morales, MSN, RN, CLNC, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-379-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

Authors: Nadia Harbeck, MD; William J. Gradishar, MD; Sarah Donahue, MPH, NP, AOCNPFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/17/2023

Valid for credit through: 11/17/2024, 11:59 PM EST

processing....

A PowerPoint version of the slides from this presentation is available for use as a professional resource from Medscape Education.

  • Print